Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Uwe Peters

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Bioorganic & Medicinal Chemistry Letters|August 21, 2010
Pyrido pyrimidinones as selective agonists of the high affinity niacin receptor GPR109A: optimization of in vitro activityJens-Uwe Peters, Holger Kühne, Henrietta Dehmlow, et al.
Bioorganic & Medicinal Chemistry Letters|June 5, 2004
An aminomethylpyrimidine DPP-IV inhibitor with improved propertiesJens-Uwe Peters, Daniel Hunziker, Holger Fischer, et al.
Bioorganic & Medicinal Chemistry|September 5, 2024
Discovery, synthesis and SAR of 2-acyl-1-biarylmethyl pyrazolidines, dual orexin receptor antagonists designed as fast and short-acting sleeping drugsJean-Philippe Surivet, Melanie Kessler, Catherine Vaillant, et al.
Journal of Pharmacological and Toxicological Methods|July 9, 2019
Safety screening in early drug discovery: An optimized assay panelStefanie Bendels, Caterina Bissantz, Bernhard Fasching, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 26, 2005
Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activityRichard H P Porter, Georg Jaeschke, Will Spooren, et al.
Bioorganic & Medicinal Chemistry Letters|January 2, 2007
Synthesis and biological evaluation of fenobam analogs as mGlu5 receptor antagonistsGeorg Jaeschke, Richard Porter, Bernd Büttelmann, et al.
Chemmedchem|November 13, 2007
Metabolite identification via LC-SPE-NMR-MS of the in vitro biooxidation products of a lead mGlu5 allosteric antagonist and impact on the improvement of metabolic stability in the seriesSimona M Ceccarelli, Götz Schlotterbeck, Patrick Boissin, et al.
Bioorganic & Medicinal Chemistry|March 6, 2025
Discovery of IDOR-1117-1680, a dual orexin receptor antagonist with fast onset and short duration of action for the treatment of insomniaJean-Philippe Surivet, Elise M Jacob, Melanie Kessler, et al.
Journal of Medicinal Chemistry|January 8, 2015
Metabotropic glutamate receptor 5 negative allosteric modulators: discovery of 2-chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, RO4917523), a promising novel medicine for psychiatric diseasesGeorg Jaeschke, Sabine Kolczewski, Will Spooren, et al.
Plos One|November 25, 2020
Source attribution of community-acquired cases of Legionnaires' disease-results from the German LeTriWa study; Berlin, 2016-2019Udo Buchholz, Heiko Juergen Jahn, Bonita Brodhun, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Bioorganic & Medicinal Chemistry Letters|August 21, 2010
Pyrido pyrimidinones as selective agonists of the high affinity niacin receptor GPR109A: optimization of in vitro activityJens-Uwe Peters, Holger Kühne, Henrietta Dehmlow, et al.
Bioorganic & Medicinal Chemistry Letters|June 5, 2004
An aminomethylpyrimidine DPP-IV inhibitor with improved propertiesJens-Uwe Peters, Daniel Hunziker, Holger Fischer, et al.
Bioorganic & Medicinal Chemistry|September 5, 2024
Discovery, synthesis and SAR of 2-acyl-1-biarylmethyl pyrazolidines, dual orexin receptor antagonists designed as fast and short-acting sleeping drugsJean-Philippe Surivet, Melanie Kessler, Catherine Vaillant, et al.
Journal of Pharmacological and Toxicological Methods|July 9, 2019
Safety screening in early drug discovery: An optimized assay panelStefanie Bendels, Caterina Bissantz, Bernhard Fasching, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 26, 2005
Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activityRichard H P Porter, Georg Jaeschke, Will Spooren, et al.
Bioorganic & Medicinal Chemistry Letters|January 2, 2007
Synthesis and biological evaluation of fenobam analogs as mGlu5 receptor antagonistsGeorg Jaeschke, Richard Porter, Bernd Büttelmann, et al.
Chemmedchem|November 13, 2007
Metabolite identification via LC-SPE-NMR-MS of the in vitro biooxidation products of a lead mGlu5 allosteric antagonist and impact on the improvement of metabolic stability in the seriesSimona M Ceccarelli, Götz Schlotterbeck, Patrick Boissin, et al.
Bioorganic & Medicinal Chemistry|March 6, 2025
Discovery of IDOR-1117-1680, a dual orexin receptor antagonist with fast onset and short duration of action for the treatment of insomniaJean-Philippe Surivet, Elise M Jacob, Melanie Kessler, et al.
Journal of Medicinal Chemistry|January 8, 2015
Metabotropic glutamate receptor 5 negative allosteric modulators: discovery of 2-chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, RO4917523), a promising novel medicine for psychiatric diseasesGeorg Jaeschke, Sabine Kolczewski, Will Spooren, et al.
Plos One|November 25, 2020
Source attribution of community-acquired cases of Legionnaires' disease-results from the German LeTriWa study; Berlin, 2016-2019Udo Buchholz, Heiko Juergen Jahn, Bonita Brodhun, et al.
Pageof 5